Search

Search Constraints

You searched for: Author/Creator Mo, Annie X.

Search Results

1. Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Issue 8 (22nd February 2021)